PARP1 and breast cancer: As shown in Table 3, the results showed no significant association between ADPRT Val762Ala polymorphism and breast cancer risk (OR = 0.960, 95% CI = 0.845–1.090 for Val/Ala vs. Val/Val; OR = 0.897, 95% CI = 0.683–1.178 for Ala/Ala vs. Val/Val; OR = 0.953, 95% CI = 0.843–1.077 for dominant model; OR = 1.084, 95% CI = 0.838–1.403 for recessive model) (Figure 2).